Intra-Cellular Therapies Inc (ITCI)
77.64
+0.67
(+0.87%)
USD |
NASDAQ |
Sep 20, 16:00
77.72
+0.08
(+0.10%)
After-Hours: 20:00
Intra-Cellular Therapies Gross Profit Margin (Quarterly): 92.96% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 92.96% |
March 31, 2024 | 93.16% |
December 31, 2023 | 91.86% |
September 30, 2023 | 92.74% |
June 30, 2023 | 93.50% |
March 31, 2023 | 92.87% |
December 31, 2022 | 92.24% |
September 30, 2022 | 91.86% |
June 30, 2022 | 91.56% |
Date | Value |
---|---|
March 31, 2022 | 90.92% |
December 31, 2021 | 90.05% |
September 30, 2021 | 90.74% |
June 30, 2021 | 89.27% |
March 31, 2021 | 90.66% |
December 31, 2020 | 90.80% |
September 30, 2020 | 92.45% |
June 30, 2020 | 93.15% |
March 31, 2020 | 92.15% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
89.27%
Minimum
Jun 2021
93.50%
Maximum
Jun 2023
91.83%
Average
92.00%
Median
Gross Profit Margin (Quarterly) Benchmarks
AbbVie Inc | 70.94% |
ACADIA Pharmaceuticals Inc | 92.47% |
EyePoint Pharmaceuticals Inc | 85.22% |
Madrigal Pharmaceuticals Inc | 95.66% |
Ovid Therapeutics Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | -11.90% |
Return on Assets | -9.97% |
Return on Invested Capital | -11.90% |
Profit Margin (Quarterly) | -10.06% |
Operating Margin (Quarterly) | -17.19% |
Return on Net Operating Assets | -52.87% |